Search for a trial

A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in patients with treatment-resistant depression.

To determine the efficacy of a single day individualized dosing regimen (IDR) of GH001 compared with placebo in improving depressive symptoms as assessed by MADRS in patients with treatment-resistant depression (TRD) at the end of the 7-day double-…